nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—EPHA7—lung cancer	0.107	0.254	CbGaD
Crizotinib—ROS1—lung cancer	0.0616	0.146	CbGaD
Crizotinib—TXK—lung cancer	0.0524	0.124	CbGaD
Crizotinib—AXL—lung cancer	0.0467	0.11	CbGaD
Crizotinib—FGR—lung cancer	0.0397	0.0939	CbGaD
Crizotinib—MET—lung cancer	0.033	0.0781	CbGaD
Crizotinib—TNK1—Erlotinib—lung cancer	0.0315	0.093	CbGbCtD
Crizotinib—JAK3—Erlotinib—lung cancer	0.0315	0.093	CbGbCtD
Crizotinib—IGF1R—lung cancer	0.0312	0.0737	CbGaD
Crizotinib—IRAK1—Gefitinib—lung cancer	0.0306	0.0903	CbGbCtD
Crizotinib—ALK—lung cancer	0.0283	0.0669	CbGaD
Crizotinib—EPHA6—Gefitinib—lung cancer	0.027	0.0798	CbGbCtD
Crizotinib—LTK—Erlotinib—lung cancer	0.025	0.0739	CbGbCtD
Crizotinib—STK10—Gefitinib—lung cancer	0.0243	0.0717	CbGbCtD
Crizotinib—SLK—Erlotinib—lung cancer	0.0209	0.0618	CbGbCtD
Crizotinib—MAP3K19—Gefitinib—lung cancer	0.0203	0.06	CbGbCtD
Crizotinib—SRC—lung cancer	0.0189	0.0446	CbGaD
Crizotinib—FLT3—Erlotinib—lung cancer	0.0181	0.0534	CbGbCtD
Crizotinib—EPHA6—Erlotinib—lung cancer	0.016	0.0472	CbGbCtD
Crizotinib—AURKA—Doxorubicin—lung cancer	0.0155	0.0459	CbGbCtD
Crizotinib—ABL2—Erlotinib—lung cancer	0.0144	0.0424	CbGbCtD
Crizotinib—STK10—Erlotinib—lung cancer	0.0144	0.0424	CbGbCtD
Crizotinib—MAP3K19—Erlotinib—lung cancer	0.012	0.0355	CbGbCtD
Crizotinib—ABL1—Erlotinib—lung cancer	0.0104	0.0307	CbGbCtD
Crizotinib—ABCB1—lung cancer	0.00386	0.00912	CbGaD
Crizotinib—CYP3A5—Gefitinib—lung cancer	0.00222	0.00656	CbGbCtD
Crizotinib—CYP3A5—Teniposide—lung cancer	0.00215	0.00636	CbGbCtD
Crizotinib—ABCB1—Topotecan—lung cancer	0.00158	0.00467	CbGbCtD
Crizotinib—ABCB1—Gefitinib—lung cancer	0.00145	0.00427	CbGbCtD
Crizotinib—CYP3A5—Erlotinib—lung cancer	0.00131	0.00388	CbGbCtD
Crizotinib—CYP3A5—Paclitaxel—lung cancer	0.0012	0.00355	CbGbCtD
Crizotinib—CYP3A5—Irinotecan—lung cancer	0.00119	0.0035	CbGbCtD
Crizotinib—ABCB1—Vinorelbine—lung cancer	0.00111	0.00329	CbGbCtD
Crizotinib—CYP3A5—Etoposide—lung cancer	0.00095	0.00281	CbGbCtD
Crizotinib—CYP3A4—Topotecan—lung cancer	0.000947	0.0028	CbGbCtD
Crizotinib—CYP3A5—Docetaxel—lung cancer	0.00087	0.00257	CbGbCtD
Crizotinib—CYP3A4—Gefitinib—lung cancer	0.000867	0.00256	CbGbCtD
Crizotinib—ABCB1—Gemcitabine—lung cancer	0.000866	0.00256	CbGbCtD
Crizotinib—ABCB1—Erlotinib—lung cancer	0.000855	0.00253	CbGbCtD
Crizotinib—CYP3A4—Teniposide—lung cancer	0.00084	0.00248	CbGbCtD
Crizotinib—ABCB1—Paclitaxel—lung cancer	0.000783	0.00231	CbGbCtD
Crizotinib—ABCB1—Irinotecan—lung cancer	0.000772	0.00228	CbGbCtD
Crizotinib—ABCB1—Vinblastine—lung cancer	0.000687	0.00203	CbGbCtD
Crizotinib—CYP3A4—Vinorelbine—lung cancer	0.000668	0.00197	CbGbCtD
Crizotinib—ABCB1—Cisplatin—lung cancer	0.00063	0.00186	CbGbCtD
Crizotinib—ABCB1—Etoposide—lung cancer	0.000619	0.00183	CbGbCtD
Crizotinib—ABCB1—Docetaxel—lung cancer	0.000566	0.00167	CbGbCtD
Crizotinib—CYP3A4—Erlotinib—lung cancer	0.000512	0.00151	CbGbCtD
Crizotinib—CYP3A4—Paclitaxel—lung cancer	0.000469	0.00139	CbGbCtD
Crizotinib—CYP3A4—Irinotecan—lung cancer	0.000463	0.00137	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—lung cancer	0.000422	0.00125	CbGbCtD
Crizotinib—CYP3A4—Vinblastine—lung cancer	0.000411	0.00121	CbGbCtD
Crizotinib—ABCB1—Methotrexate—lung cancer	0.000409	0.00121	CbGbCtD
Crizotinib—CYP3A4—Etoposide—lung cancer	0.000371	0.00109	CbGbCtD
Crizotinib—CYP3A4—Docetaxel—lung cancer	0.000339	0.001	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—lung cancer	0.000253	0.000747	CbGbCtD
Crizotinib—CASK—Irinotecan—Topotecan—lung cancer	0.000247	0.117	CbGdCrCtD
Crizotinib—IGF1R—Irinotecan—Topotecan—lung cancer	0.000232	0.11	CbGdCrCtD
Crizotinib—FGR—respiratory system—lung cancer	0.000209	0.00381	CbGeAlD
Crizotinib—AXL—respiratory system—lung cancer	0.000208	0.00379	CbGeAlD
Crizotinib—TESK1—trachea—lung cancer	0.000204	0.00373	CbGeAlD
Crizotinib—BMP2K—bronchus—lung cancer	0.000202	0.00369	CbGeAlD
Crizotinib—MET—lung—lung cancer	0.000199	0.00363	CbGeAlD
Crizotinib—EPHB4—respiratory system—lung cancer	0.000199	0.00363	CbGeAlD
Crizotinib—TIE1—cardiac atrium—lung cancer	0.000199	0.00363	CbGeAlD
Crizotinib—PTK2—Irinotecan—Topotecan—lung cancer	0.000198	0.0935	CbGdCrCtD
Crizotinib—JAK2—respiratory system—lung cancer	0.000197	0.0036	CbGeAlD
Crizotinib—RIPK2—epithelium—lung cancer	0.000196	0.00359	CbGeAlD
Crizotinib—EPHA2—respiratory system—lung cancer	0.000195	0.00356	CbGeAlD
Crizotinib—LIMK2—trachea—lung cancer	0.000194	0.00355	CbGeAlD
Crizotinib—NUAK2—trachea—lung cancer	0.000194	0.00354	CbGeAlD
Crizotinib—RIPK2—bronchus—lung cancer	0.000193	0.00353	CbGeAlD
Crizotinib—IGF1R—Topotecan—Irinotecan—lung cancer	0.000193	0.0914	CbGdCrCtD
Crizotinib—ACVR1—trachea—lung cancer	0.000192	0.00351	CbGeAlD
Crizotinib—CDK7—lung—lung cancer	0.000192	0.00351	CbGeAlD
Crizotinib—TESK1—cardiac atrium—lung cancer	0.000192	0.0035	CbGeAlD
Crizotinib—PLK4—bone marrow—lung cancer	0.000191	0.00349	CbGeAlD
Crizotinib—TAOK2—lung—lung cancer	0.000191	0.00348	CbGeAlD
Crizotinib—TEK—respiratory system—lung cancer	0.00019	0.00347	CbGeAlD
Crizotinib—EPHA4—bronchus—lung cancer	0.000187	0.00341	CbGeAlD
Crizotinib—ACVR1B—lung—lung cancer	0.000184	0.00335	CbGeAlD
Crizotinib—EPHA3—lung—lung cancer	0.000184	0.00335	CbGeAlD
Crizotinib—PTK2—epithelium—lung cancer	0.000182	0.00333	CbGeAlD
Crizotinib—ACVR1—cardiac atrium—lung cancer	0.000181	0.0033	CbGeAlD
Crizotinib—MAP3K12—cardiac atrium—lung cancer	0.000181	0.0033	CbGeAlD
Crizotinib—ABL1—mammary gland—lung cancer	0.00018	0.00328	CbGeAlD
Crizotinib—PTK2—bronchus—lung cancer	0.00018	0.00328	CbGeAlD
Crizotinib—TBK1—bronchus—lung cancer	0.00018	0.00328	CbGeAlD
Crizotinib—NEK9—lymph node—lung cancer	0.000179	0.00327	CbGeAlD
Crizotinib—TYK2—bronchus—lung cancer	0.000178	0.00326	CbGeAlD
Crizotinib—STK35—cardiac atrium—lung cancer	0.000177	0.00323	CbGeAlD
Crizotinib—IRAK1—bronchus—lung cancer	0.000176	0.00321	CbGeAlD
Crizotinib—MAP4K1—bone marrow—lung cancer	0.000176	0.00321	CbGeAlD
Crizotinib—YES1—respiratory system—lung cancer	0.000176	0.00321	CbGeAlD
Crizotinib—RPS6KB1—epithelium—lung cancer	0.000175	0.0032	CbGeAlD
Crizotinib—JAK3—lung—lung cancer	0.000175	0.0032	CbGeAlD
Crizotinib—DCLK1—lung—lung cancer	0.000174	0.00318	CbGeAlD
Crizotinib—STK10—respiratory system—lung cancer	0.000174	0.00318	CbGeAlD
Crizotinib—RIPK2—trachea—lung cancer	0.000174	0.00317	CbGeAlD
Crizotinib—TAOK3—respiratory system—lung cancer	0.000173	0.00316	CbGeAlD
Crizotinib—PLK4—lung—lung cancer	0.000173	0.00316	CbGeAlD
Crizotinib—RPS6KB1—bronchus—lung cancer	0.000173	0.00315	CbGeAlD
Crizotinib—STK4—lung—lung cancer	0.000172	0.00314	CbGeAlD
Crizotinib—LCK—bronchus—lung cancer	0.000172	0.00314	CbGeAlD
Crizotinib—MAP4K2—bone marrow—lung cancer	0.00017	0.0031	CbGeAlD
Crizotinib—SRC—respiratory system—lung cancer	0.000169	0.00308	CbGeAlD
Crizotinib—EPHA4—trachea—lung cancer	0.000168	0.00307	CbGeAlD
Crizotinib—EPHB4—epithelium—lung cancer	0.000166	0.00303	CbGeAlD
Crizotinib—JAK2—epithelium—lung cancer	0.000165	0.00301	CbGeAlD
Crizotinib—SLK—bronchus—lung cancer	0.000165	0.00301	CbGeAlD
Crizotinib—EPHB4—bronchus—lung cancer	0.000163	0.00298	CbGeAlD
Crizotinib—PRKD1—lymph node—lung cancer	0.000163	0.00298	CbGeAlD
Crizotinib—AURKA—bone marrow—lung cancer	0.000163	0.00298	CbGeAlD
Crizotinib—RIPK2—cardiac atrium—lung cancer	0.000163	0.00298	CbGeAlD
Crizotinib—EPHA2—epithelium—lung cancer	0.000163	0.00297	CbGeAlD
Crizotinib—FER—lung—lung cancer	0.000162	0.00297	CbGeAlD
Crizotinib—ALK—lung—lung cancer	0.000162	0.00297	CbGeAlD
Crizotinib—JAK2—bronchus—lung cancer	0.000162	0.00296	CbGeAlD
Crizotinib—PTK2—trachea—lung cancer	0.000161	0.00294	CbGeAlD
Crizotinib—TBK1—trachea—lung cancer	0.000161	0.00294	CbGeAlD
Crizotinib—LIMK1—lymph node—lung cancer	0.000161	0.00294	CbGeAlD
Crizotinib—TNK1—lung—lung cancer	0.000161	0.00294	CbGeAlD
Crizotinib—EPHA2—bronchus—lung cancer	0.00016	0.00293	CbGeAlD
Crizotinib—TYK2—trachea—lung cancer	0.00016	0.00292	CbGeAlD
Crizotinib—MAP4K1—lung—lung cancer	0.000159	0.00291	CbGeAlD
Crizotinib—BMPR1B—lung—lung cancer	0.000159	0.00291	CbGeAlD
Crizotinib—MAP3K19—lung—lung cancer	0.000159	0.00291	CbGeAlD
Crizotinib—TEK—epithelium—lung cancer	0.000159	0.0029	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—lung cancer	0.000158	0.00288	CbGeAlD
Crizotinib—MERTK—bone marrow—lung cancer	0.000158	0.00288	CbGeAlD
Crizotinib—PRKD3—lymph node—lung cancer	0.000157	0.00287	CbGeAlD
Crizotinib—MAP4K5—bronchus—lung cancer	0.000156	0.00286	CbGeAlD
Crizotinib—MAP3K3—bronchus—lung cancer	0.000156	0.00286	CbGeAlD
Crizotinib—TEK—bronchus—lung cancer	0.000156	0.00286	CbGeAlD
Crizotinib—IGF1R—lung—lung cancer	0.000156	0.00285	CbGeAlD
Crizotinib—TNK2—lung—lung cancer	0.000156	0.00285	CbGeAlD
Crizotinib—CDK7—Topotecan—Irinotecan—lung cancer	0.000156	0.0736	CbGdCrCtD
Crizotinib—RPS6KB1—trachea—lung cancer	0.000155	0.00283	CbGeAlD
Crizotinib—LCK—trachea—lung cancer	0.000154	0.00282	CbGeAlD
Crizotinib—MAP4K2—lung—lung cancer	0.000154	0.00281	CbGeAlD
Crizotinib—NUAK2—bone marrow—lung cancer	0.000154	0.0028	CbGeAlD
Crizotinib—AXL—trachea—lung cancer	0.000154	0.0028	CbGeAlD
Crizotinib—DSTYK—lymph node—lung cancer	0.000153	0.0028	CbGeAlD
Crizotinib—FLT3—bone marrow—lung cancer	0.000152	0.00278	CbGeAlD
Crizotinib—ACVR1—bone marrow—lung cancer	0.000152	0.00278	CbGeAlD
Crizotinib—TIE1—lung—lung cancer	0.000152	0.00277	CbGeAlD
Crizotinib—STK3—lung—lung cancer	0.000152	0.00277	CbGeAlD
Crizotinib—CSF1R—respiratory system—lung cancer	0.000152	0.00277	CbGeAlD
Crizotinib—BLK—lymph node—lung cancer	0.000152	0.00277	CbGeAlD
Crizotinib—TBK1—cardiac atrium—lung cancer	0.000151	0.00277	CbGeAlD
Crizotinib—TYK2—cardiac atrium—lung cancer	0.00015	0.00275	CbGeAlD
Crizotinib—LTK—lymph node—lung cancer	0.00015	0.00274	CbGeAlD
Crizotinib—CASK—lymph node—lung cancer	0.00015	0.00274	CbGeAlD
Crizotinib—EPHB6—bronchus—lung cancer	0.000149	0.00273	CbGeAlD
Crizotinib—AURKA—lung—lung cancer	0.000148	0.0027	CbGeAlD
Crizotinib—SLK—trachea—lung cancer	0.000148	0.0027	CbGeAlD
Crizotinib—TESK1—lung—lung cancer	0.000147	0.00268	CbGeAlD
Crizotinib—EPHB4—trachea—lung cancer	0.000147	0.00268	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—lung cancer	0.000146	0.00266	CbGeAlD
Crizotinib—JAK2—trachea—lung cancer	0.000146	0.00266	CbGeAlD
Crizotinib—MAPK7—lymph node—lung cancer	0.000145	0.00265	CbGeAlD
Crizotinib—TXK—lymph node—lung cancer	0.000145	0.00265	CbGeAlD
Crizotinib—YES1—bronchus—lung cancer	0.000144	0.00264	CbGeAlD
Crizotinib—AXL—cardiac atrium—lung cancer	0.000144	0.00263	CbGeAlD
Crizotinib—EPHA2—trachea—lung cancer	0.000144	0.00263	CbGeAlD
Crizotinib—BMP2K—bone marrow—lung cancer	0.000144	0.00263	CbGeAlD
Crizotinib—FES—lymph node—lung cancer	0.000144	0.00262	CbGeAlD
Crizotinib—STK10—bronchus—lung cancer	0.000143	0.00261	CbGeAlD
Crizotinib—MERTK—lung—lung cancer	0.000143	0.00261	CbGeAlD
Crizotinib—TAOK3—bronchus—lung cancer	0.000143	0.0026	CbGeAlD
Crizotinib—SRC—epithelium—lung cancer	0.000141	0.00258	CbGeAlD
Crizotinib—MAP4K5—trachea—lung cancer	0.00014	0.00256	CbGeAlD
Crizotinib—MAP3K3—trachea—lung cancer	0.00014	0.00256	CbGeAlD
Crizotinib—LIMK2—lung—lung cancer	0.00014	0.00255	CbGeAlD
Crizotinib—NUAK2—lung—lung cancer	0.000139	0.00254	CbGeAlD
Crizotinib—PTK2B—bone marrow—lung cancer	0.000139	0.00254	CbGeAlD
Crizotinib—SLK—cardiac atrium—lung cancer	0.000139	0.00254	CbGeAlD
Crizotinib—ACVR1—lung—lung cancer	0.000138	0.00252	CbGeAlD
Crizotinib—FLT3—lung—lung cancer	0.000138	0.00252	CbGeAlD
Crizotinib—MAP3K12—lung—lung cancer	0.000138	0.00252	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—lung cancer	0.000138	0.00252	CbGeAlD
Crizotinib—RIPK2—bone marrow—lung cancer	0.000138	0.00252	CbGeAlD
Crizotinib—JAK2—cardiac atrium—lung cancer	0.000137	0.0025	CbGeAlD
Crizotinib—MET—lymph node—lung cancer	0.000136	0.00248	CbGeAlD
Crizotinib—STK35—lung—lung cancer	0.000135	0.00247	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—lung cancer	0.000135	0.00247	CbGeAlD
Crizotinib—EPHB6—trachea—lung cancer	0.000134	0.00245	CbGeAlD
Crizotinib—TEK—cardiac atrium—lung cancer	0.000132	0.00241	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—lung cancer	0.000132	0.00241	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—lung cancer	0.000132	0.00241	CbGeAlD
Crizotinib—ABL2—lung—lung cancer	0.000132	0.00241	CbGeAlD
Crizotinib—CDK7—lymph node—lung cancer	0.000131	0.0024	CbGeAlD
Crizotinib—MAP3K2—bone marrow—lung cancer	0.000131	0.00238	CbGeAlD
Crizotinib—TAOK2—lymph node—lung cancer	0.00013	0.00238	CbGeAlD
Crizotinib—BMP2K—lung—lung cancer	0.00013	0.00238	CbGeAlD
Crizotinib—YES1—trachea—lung cancer	0.00013	0.00237	CbGeAlD
Crizotinib—TAOK3—trachea—lung cancer	0.000128	0.00234	CbGeAlD
Crizotinib—TBK1—bone marrow—lung cancer	0.000128	0.00234	CbGeAlD
Crizotinib—TYK2—bone marrow—lung cancer	0.000127	0.00232	CbGeAlD
Crizotinib—EPHB6—cardiac atrium—lung cancer	0.000126	0.0023	CbGeAlD
Crizotinib—PTK2B—lung—lung cancer	0.000126	0.0023	CbGeAlD
Crizotinib—EPHA3—lymph node—lung cancer	0.000126	0.00229	CbGeAlD
Crizotinib—ACVR1B—lymph node—lung cancer	0.000126	0.00229	CbGeAlD
Crizotinib—IRAK1—bone marrow—lung cancer	0.000125	0.00229	CbGeAlD
Crizotinib—RIPK2—lung—lung cancer	0.000125	0.00228	CbGeAlD
Crizotinib—CSF1R—bronchus—lung cancer	0.000125	0.00228	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—lung cancer	0.000123	0.00225	CbGeAlD
Crizotinib—FGR—bone marrow—lung cancer	0.000122	0.00223	CbGeAlD
Crizotinib—LCK—bone marrow—lung cancer	0.000122	0.00223	CbGeAlD
Crizotinib—YES1—cardiac atrium—lung cancer	0.000122	0.00222	CbGeAlD
Crizotinib—EPHA4—lung—lung cancer	0.000121	0.0022	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—lung cancer	0.00012	0.0022	CbGeAlD
Crizotinib—ABL1—respiratory system—lung cancer	0.00012	0.00219	CbGeAlD
Crizotinib—JAK3—lymph node—lung cancer	0.00012	0.00219	CbGeAlD
Crizotinib—DCLK1—lymph node—lung cancer	0.000119	0.00217	CbGeAlD
Crizotinib—MAP3K2—lung—lung cancer	0.000118	0.00216	CbGeAlD
Crizotinib—PLK4—lymph node—lung cancer	0.000118	0.00216	CbGeAlD
Crizotinib—STK4—lymph node—lung cancer	0.000118	0.00215	CbGeAlD
Crizotinib—SLK—bone marrow—lung cancer	0.000117	0.00214	CbGeAlD
Crizotinib—SRC—cardiac atrium—lung cancer	0.000117	0.00214	CbGeAlD
Crizotinib—EPHB4—bone marrow—lung cancer	0.000116	0.00213	CbGeAlD
Crizotinib—PTK2—lung—lung cancer	0.000116	0.00212	CbGeAlD
Crizotinib—TBK1—lung—lung cancer	0.000116	0.00212	CbGeAlD
Crizotinib—JAK2—bone marrow—lung cancer	0.000116	0.00211	CbGeAlD
Crizotinib—TYK2—lung—lung cancer	0.000115	0.0021	CbGeAlD
Crizotinib—IRAK1—lung—lung cancer	0.000114	0.00207	CbGeAlD
Crizotinib—CSF1R—trachea—lung cancer	0.000112	0.00205	CbGeAlD
Crizotinib—RPS6KB1—lung—lung cancer	0.000111	0.00204	CbGeAlD
Crizotinib—MAP3K3—bone marrow—lung cancer	0.000111	0.00203	CbGeAlD
Crizotinib—MAP4K5—bone marrow—lung cancer	0.000111	0.00203	CbGeAlD
Crizotinib—ALK—lymph node—lung cancer	0.000111	0.00203	CbGeAlD
Crizotinib—FER—lymph node—lung cancer	0.000111	0.00203	CbGeAlD
Crizotinib—LCK—lung—lung cancer	0.000111	0.00202	CbGeAlD
Crizotinib—FGR—lung—lung cancer	0.000111	0.00202	CbGeAlD
Crizotinib—AXL—lung—lung cancer	0.00011	0.00201	CbGeAlD
Crizotinib—TNK1—lymph node—lung cancer	0.00011	0.00201	CbGeAlD
Crizotinib—BMPR1B—lymph node—lung cancer	0.000109	0.00199	CbGeAlD
Crizotinib—MAP4K1—lymph node—lung cancer	0.000109	0.00199	CbGeAlD
Crizotinib—TNK2—lymph node—lung cancer	0.000107	0.00195	CbGeAlD
Crizotinib—IGF1R—lymph node—lung cancer	0.000107	0.00195	CbGeAlD
Crizotinib—SLK—lung—lung cancer	0.000106	0.00194	CbGeAlD
Crizotinib—EPHB4—lung—lung cancer	0.000105	0.00193	CbGeAlD
Crizotinib—MAP4K2—lymph node—lung cancer	0.000105	0.00192	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—lung cancer	0.000105	0.00192	CbGeAlD
Crizotinib—JAK2—lung—lung cancer	0.000105	0.00191	CbGeAlD
Crizotinib—STK3—lymph node—lung cancer	0.000104	0.0019	CbGeAlD
Crizotinib—TIE1—lymph node—lung cancer	0.000104	0.0019	CbGeAlD
Crizotinib—EPHA2—lung—lung cancer	0.000103	0.00189	CbGeAlD
Crizotinib—YES1—bone marrow—lung cancer	0.000103	0.00188	CbGeAlD
Crizotinib—STK10—bone marrow—lung cancer	0.000102	0.00186	CbGeAlD
Crizotinib—TAOK3—bone marrow—lung cancer	0.000102	0.00185	CbGeAlD
Crizotinib—PLK4—Topotecan—Irinotecan—lung cancer	0.000101	0.048	CbGdCrCtD
Crizotinib—AURKA—lymph node—lung cancer	0.000101	0.00185	CbGeAlD
Crizotinib—MAP4K5—lung—lung cancer	0.000101	0.00184	CbGeAlD
Crizotinib—TEK—lung—lung cancer	0.000101	0.00184	CbGeAlD
Crizotinib—MAP3K3—lung—lung cancer	0.000101	0.00184	CbGeAlD
Crizotinib—PLK4—Etoposide—Teniposide—lung cancer	0.000101	0.0477	CbGdCrCtD
Crizotinib—TESK1—lymph node—lung cancer	0.0001	0.00183	CbGeAlD
Crizotinib—ABL1—bronchus—lung cancer	9.86e-05	0.0018	CbGeAlD
Crizotinib—MERTK—lymph node—lung cancer	9.76e-05	0.00178	CbGeAlD
Crizotinib—EPHB6—lung—lung cancer	9.64e-05	0.00176	CbGeAlD
Crizotinib—AURKA—Irinotecan—Topotecan—lung cancer	9.56e-05	0.0452	CbGdCrCtD
Crizotinib—LIMK2—lymph node—lung cancer	9.55e-05	0.00174	CbGeAlD
Crizotinib—NUAK2—lymph node—lung cancer	9.52e-05	0.00174	CbGeAlD
Crizotinib—MAP3K12—lymph node—lung cancer	9.45e-05	0.00173	CbGeAlD
Crizotinib—ACVR1—lymph node—lung cancer	9.45e-05	0.00173	CbGeAlD
Crizotinib—FLT3—lymph node—lung cancer	9.45e-05	0.00173	CbGeAlD
Crizotinib—YES1—lung—lung cancer	9.32e-05	0.0017	CbGeAlD
Crizotinib—STK35—lymph node—lung cancer	9.26e-05	0.00169	CbGeAlD
Crizotinib—CASK—Teniposide—Etoposide—lung cancer	9.25e-05	0.0438	CbGdCrCtD
Crizotinib—STK10—lung—lung cancer	9.24e-05	0.00169	CbGeAlD
Crizotinib—TAOK3—lung—lung cancer	9.2e-05	0.00168	CbGeAlD
Crizotinib—ABL2—lymph node—lung cancer	9.02e-05	0.00165	CbGeAlD
Crizotinib—SRC—lung—lung cancer	8.97e-05	0.00164	CbGeAlD
Crizotinib—BMP2K—lymph node—lung cancer	8.91e-05	0.00163	CbGeAlD
Crizotinib—CSF1R—bone marrow—lung cancer	8.88e-05	0.00162	CbGeAlD
Crizotinib—ABL1—trachea—lung cancer	8.86e-05	0.00162	CbGeAlD
Crizotinib—PTK2B—lymph node—lung cancer	8.61e-05	0.00157	CbGeAlD
Crizotinib—RIPK2—lymph node—lung cancer	8.54e-05	0.00156	CbGeAlD
Crizotinib—ABL1—Topotecan—Irinotecan—lung cancer	8.53e-05	0.0404	CbGdCrCtD
Crizotinib—ABL1—cardiac atrium—lung cancer	8.32e-05	0.00152	CbGeAlD
Crizotinib—EPHA4—lymph node—lung cancer	8.25e-05	0.00151	CbGeAlD
Crizotinib—MAP3K2—lymph node—lung cancer	8.09e-05	0.00148	CbGeAlD
Crizotinib—CSF1R—lung—lung cancer	8.05e-05	0.00147	CbGeAlD
Crizotinib—AURKA—Topotecan—Irinotecan—lung cancer	7.94e-05	0.0376	CbGdCrCtD
Crizotinib—TBK1—lymph node—lung cancer	7.92e-05	0.00145	CbGeAlD
Crizotinib—PTK2—lymph node—lung cancer	7.92e-05	0.00145	CbGeAlD
Crizotinib—AURKA—Etoposide—Teniposide—lung cancer	7.89e-05	0.0373	CbGdCrCtD
Crizotinib—TYK2—lymph node—lung cancer	7.87e-05	0.00144	CbGeAlD
Crizotinib—IRAK1—lymph node—lung cancer	7.77e-05	0.00142	CbGeAlD
Crizotinib—RPS6KB1—lymph node—lung cancer	7.62e-05	0.00139	CbGeAlD
Crizotinib—LCK—lymph node—lung cancer	7.58e-05	0.00138	CbGeAlD
Crizotinib—FGR—lymph node—lung cancer	7.58e-05	0.00138	CbGeAlD
Crizotinib—AXL—lymph node—lung cancer	7.55e-05	0.00138	CbGeAlD
Crizotinib—SLK—lymph node—lung cancer	7.26e-05	0.00133	CbGeAlD
Crizotinib—EPHB4—lymph node—lung cancer	7.21e-05	0.00132	CbGeAlD
Crizotinib—JAK2—lymph node—lung cancer	7.16e-05	0.00131	CbGeAlD
Crizotinib—EPHA2—lymph node—lung cancer	7.07e-05	0.00129	CbGeAlD
Crizotinib—ABL1—bone marrow—lung cancer	7.02e-05	0.00128	CbGeAlD
Crizotinib—CYP3A5—respiratory system—lung cancer	7.01e-05	0.00128	CbGeAlD
Crizotinib—MAP3K3—lymph node—lung cancer	6.9e-05	0.00126	CbGeAlD
Crizotinib—TEK—lymph node—lung cancer	6.9e-05	0.00126	CbGeAlD
Crizotinib—MAP4K5—lymph node—lung cancer	6.9e-05	0.00126	CbGeAlD
Crizotinib—EPHB6—lymph node—lung cancer	6.6e-05	0.0012	CbGeAlD
Crizotinib—YES1—lymph node—lung cancer	6.37e-05	0.00116	CbGeAlD
Crizotinib—ABL1—lung—lung cancer	6.36e-05	0.00116	CbGeAlD
Crizotinib—STK10—lymph node—lung cancer	6.32e-05	0.00115	CbGeAlD
Crizotinib—TAOK3—lymph node—lung cancer	6.29e-05	0.00115	CbGeAlD
Crizotinib—SRC—lymph node—lung cancer	6.13e-05	0.00112	CbGeAlD
Crizotinib—AURKA—Methotrexate—Pemetrexed—lung cancer	5.66e-05	0.0268	CbGdCrCtD
Crizotinib—CSF1R—lymph node—lung cancer	5.5e-05	0.00101	CbGeAlD
Crizotinib—Oedema—Irinotecan—lung cancer	5.4e-05	0.000734	CcSEcCtD
Crizotinib—Malnutrition—Paclitaxel—lung cancer	5.4e-05	0.000734	CcSEcCtD
Crizotinib—Diarrhoea—Vinblastine—lung cancer	5.39e-05	0.000733	CcSEcCtD
Crizotinib—Dysgeusia—Etoposide—lung cancer	5.39e-05	0.000733	CcSEcCtD
Crizotinib—Leukopenia—Cisplatin—lung cancer	5.38e-05	0.000731	CcSEcCtD
Crizotinib—Infection—Irinotecan—lung cancer	5.37e-05	0.000729	CcSEcCtD
Crizotinib—Shock—Irinotecan—lung cancer	5.32e-05	0.000722	CcSEcCtD
Crizotinib—Nervous system disorder—Irinotecan—lung cancer	5.3e-05	0.00072	CcSEcCtD
Crizotinib—Dysgeusia—Paclitaxel—lung cancer	5.29e-05	0.000718	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—lung cancer	5.28e-05	0.000717	CcSEcCtD
Crizotinib—Oedema—Gemcitabine—lung cancer	5.26e-05	0.000715	CcSEcCtD
Crizotinib—Diarrhoea—Topotecan—lung cancer	5.24e-05	0.000712	CcSEcCtD
Crizotinib—Hypoaesthesia—Docetaxel—lung cancer	5.23e-05	0.000711	CcSEcCtD
Crizotinib—Infection—Gemcitabine—lung cancer	5.23e-05	0.00071	CcSEcCtD
Crizotinib—Dizziness—Vinblastine—lung cancer	5.21e-05	0.000708	CcSEcCtD
Crizotinib—Urinary tract disorder—Docetaxel—lung cancer	5.19e-05	0.000705	CcSEcCtD
Crizotinib—Diarrhoea—Erlotinib—lung cancer	5.18e-05	0.000704	CcSEcCtD
Crizotinib—Body temperature increased—Vinorelbine—lung cancer	5.18e-05	0.000704	CcSEcCtD
Crizotinib—Oedema peripheral—Docetaxel—lung cancer	5.18e-05	0.000704	CcSEcCtD
Crizotinib—Nervous system disorder—Gemcitabine—lung cancer	5.16e-05	0.000701	CcSEcCtD
Crizotinib—Urethral disorder—Docetaxel—lung cancer	5.15e-05	0.0007	CcSEcCtD
Crizotinib—Skin disorder—Gemcitabine—lung cancer	5.11e-05	0.000695	CcSEcCtD
Crizotinib—Anaemia—Etoposide—lung cancer	5.09e-05	0.000692	CcSEcCtD
Crizotinib—Vision blurred—Paclitaxel—lung cancer	5.09e-05	0.000691	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	5.08e-05	0.000691	CcSEcCtD
Crizotinib—Visual impairment—Docetaxel—lung cancer	5.07e-05	0.000688	CcSEcCtD
Crizotinib—Dizziness—Topotecan—lung cancer	5.06e-05	0.000688	CcSEcCtD
Crizotinib—Vomiting—Vinblastine—lung cancer	5.01e-05	0.000681	CcSEcCtD
Crizotinib—Dizziness—Erlotinib—lung cancer	5.01e-05	0.000681	CcSEcCtD
Crizotinib—Anaemia—Paclitaxel—lung cancer	4.99e-05	0.000678	CcSEcCtD
Crizotinib—Leukopenia—Etoposide—lung cancer	4.93e-05	0.00067	CcSEcCtD
Crizotinib—Eye disorder—Docetaxel—lung cancer	4.91e-05	0.000668	CcSEcCtD
Crizotinib—Oedema—Cisplatin—lung cancer	4.91e-05	0.000667	CcSEcCtD
Crizotinib—Cardiac disorder—Docetaxel—lung cancer	4.88e-05	0.000663	CcSEcCtD
Crizotinib—Infection—Cisplatin—lung cancer	4.87e-05	0.000662	CcSEcCtD
Crizotinib—Vomiting—Topotecan—lung cancer	4.87e-05	0.000662	CcSEcCtD
Crizotinib—Paraesthesia—Irinotecan—lung cancer	4.85e-05	0.000659	CcSEcCtD
Crizotinib—Syncope—Paclitaxel—lung cancer	4.84e-05	0.000658	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—lung cancer	4.84e-05	0.000658	CcSEcCtD
Crizotinib—Leukopenia—Paclitaxel—lung cancer	4.83e-05	0.000657	CcSEcCtD
Crizotinib—Rash—Topotecan—lung cancer	4.83e-05	0.000656	CcSEcCtD
Crizotinib—Dermatitis—Topotecan—lung cancer	4.82e-05	0.000655	CcSEcCtD
Crizotinib—Vomiting—Erlotinib—lung cancer	4.82e-05	0.000655	CcSEcCtD
Crizotinib—Dyspnoea—Irinotecan—lung cancer	4.82e-05	0.000654	CcSEcCtD
Crizotinib—Nervous system disorder—Cisplatin—lung cancer	4.81e-05	0.000654	CcSEcCtD
Crizotinib—Rash—Erlotinib—lung cancer	4.78e-05	0.000649	CcSEcCtD
Crizotinib—Dermatitis—Erlotinib—lung cancer	4.77e-05	0.000649	CcSEcCtD
Crizotinib—Skin disorder—Cisplatin—lung cancer	4.77e-05	0.000647	CcSEcCtD
Crizotinib—Dyspepsia—Irinotecan—lung cancer	4.76e-05	0.000646	CcSEcCtD
Crizotinib—Loss of consciousness—Paclitaxel—lung cancer	4.75e-05	0.000645	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—lung cancer	4.74e-05	0.000644	CcSEcCtD
Crizotinib—Mediastinal disorder—Docetaxel—lung cancer	4.74e-05	0.000644	CcSEcCtD
Crizotinib—Paraesthesia—Gemcitabine—lung cancer	4.73e-05	0.000642	CcSEcCtD
Crizotinib—Asthenia—Vinorelbine—lung cancer	4.7e-05	0.000639	CcSEcCtD
Crizotinib—Decreased appetite—Irinotecan—lung cancer	4.7e-05	0.000638	CcSEcCtD
Crizotinib—Arrhythmia—Docetaxel—lung cancer	4.7e-05	0.000638	CcSEcCtD
Crizotinib—Dyspnoea—Gemcitabine—lung cancer	4.69e-05	0.000638	CcSEcCtD
Crizotinib—Nausea—Vinblastine—lung cancer	4.68e-05	0.000636	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Irinotecan—lung cancer	4.66e-05	0.000634	CcSEcCtD
Crizotinib—Fatigue—Irinotecan—lung cancer	4.66e-05	0.000633	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	4.66e-05	0.000633	CcSEcCtD
Crizotinib—Constipation—Irinotecan—lung cancer	4.62e-05	0.000628	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—lung cancer	4.58e-05	0.000622	CcSEcCtD
Crizotinib—Malnutrition—Docetaxel—lung cancer	4.58e-05	0.000622	CcSEcCtD
Crizotinib—Decreased appetite—Gemcitabine—lung cancer	4.58e-05	0.000622	CcSEcCtD
Crizotinib—PLK4—Teniposide—Etoposide—lung cancer	4.57e-05	0.0216	CbGdCrCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	4.57e-05	0.00062	CcSEcCtD
Crizotinib—Nausea—Topotecan—lung cancer	4.55e-05	0.000618	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Gemcitabine—lung cancer	4.54e-05	0.000617	CcSEcCtD
Crizotinib—Fatigue—Gemcitabine—lung cancer	4.54e-05	0.000617	CcSEcCtD
Crizotinib—Constipation—Gemcitabine—lung cancer	4.5e-05	0.000612	CcSEcCtD
Crizotinib—Nausea—Erlotinib—lung cancer	4.5e-05	0.000612	CcSEcCtD
Crizotinib—Diarrhoea—Vinorelbine—lung cancer	4.48e-05	0.000609	CcSEcCtD
Crizotinib—Dysgeusia—Docetaxel—lung cancer	4.48e-05	0.000609	CcSEcCtD
Crizotinib—Infection—Etoposide—lung cancer	4.46e-05	0.000607	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—lung cancer	4.43e-05	0.000601	CcSEcCtD
Crizotinib—Oedema—Paclitaxel—lung cancer	4.41e-05	0.000599	CcSEcCtD
Crizotinib—Paraesthesia—Cisplatin—lung cancer	4.41e-05	0.000599	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—lung cancer	4.4e-05	0.000598	CcSEcCtD
Crizotinib—Infection—Paclitaxel—lung cancer	4.38e-05	0.000595	CcSEcCtD
Crizotinib—Dyspnoea—Cisplatin—lung cancer	4.37e-05	0.000594	CcSEcCtD
Crizotinib—Skin disorder—Etoposide—lung cancer	4.37e-05	0.000593	CcSEcCtD
Crizotinib—ABL1—lymph node—lung cancer	4.35e-05	0.000795	CbGeAlD
Crizotinib—Shock—Paclitaxel—lung cancer	4.34e-05	0.000589	CcSEcCtD
Crizotinib—Dizziness—Vinorelbine—lung cancer	4.33e-05	0.000589	CcSEcCtD
Crizotinib—Nervous system disorder—Paclitaxel—lung cancer	4.32e-05	0.000587	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—lung cancer	4.32e-05	0.000586	CcSEcCtD
Crizotinib—Skin disorder—Paclitaxel—lung cancer	4.28e-05	0.000582	CcSEcCtD
Crizotinib—Body temperature increased—Irinotecan—lung cancer	4.27e-05	0.00058	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	4.27e-05	0.00058	CcSEcCtD
Crizotinib—Decreased appetite—Cisplatin—lung cancer	4.26e-05	0.000579	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—lung cancer	4.25e-05	0.000577	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cisplatin—lung cancer	4.24e-05	0.000575	CcSEcCtD
Crizotinib—Anaemia—Docetaxel—lung cancer	4.23e-05	0.000575	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—lung cancer	4.22e-05	0.000573	CcSEcCtD
Crizotinib—Infestation—Methotrexate—lung cancer	4.22e-05	0.000573	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—lung cancer	4.2e-05	0.0199	CbGdCrCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	4.18e-05	0.000568	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—lung cancer	4.18e-05	0.000568	CcSEcCtD
Crizotinib—Vomiting—Vinorelbine—lung cancer	4.17e-05	0.000566	CcSEcCtD
Crizotinib—Body temperature increased—Gemcitabine—lung cancer	4.16e-05	0.000565	CcSEcCtD
Crizotinib—Rash—Vinorelbine—lung cancer	4.13e-05	0.000561	CcSEcCtD
Crizotinib—Dermatitis—Vinorelbine—lung cancer	4.13e-05	0.000561	CcSEcCtD
Crizotinib—Syncope—Docetaxel—lung cancer	4.1e-05	0.000558	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—lung cancer	4.1e-05	0.000557	CcSEcCtD
Crizotinib—Paraesthesia—Etoposide—lung cancer	4.04e-05	0.000548	CcSEcCtD
Crizotinib—Loss of consciousness—Docetaxel—lung cancer	4.02e-05	0.000547	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—lung cancer	4.01e-05	0.000544	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—lung cancer	3.99e-05	0.000542	CcSEcCtD
Crizotinib—Paraesthesia—Paclitaxel—lung cancer	3.96e-05	0.000538	CcSEcCtD
Crizotinib—Dyspnoea—Paclitaxel—lung cancer	3.93e-05	0.000534	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—lung cancer	3.91e-05	0.000531	CcSEcCtD
Crizotinib—Nausea—Vinorelbine—lung cancer	3.89e-05	0.000529	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—lung cancer	3.88e-05	0.000527	CcSEcCtD
Crizotinib—Dyspepsia—Paclitaxel—lung cancer	3.88e-05	0.000527	CcSEcCtD
Crizotinib—Body temperature increased—Cisplatin—lung cancer	3.88e-05	0.000527	CcSEcCtD
Crizotinib—Asthenia—Irinotecan—lung cancer	3.88e-05	0.000527	CcSEcCtD
Crizotinib—Fatigue—Etoposide—lung cancer	3.87e-05	0.000526	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	3.87e-05	0.000526	CcSEcCtD
Crizotinib—Constipation—Etoposide—lung cancer	3.84e-05	0.000522	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—lung cancer	3.83e-05	0.000521	CcSEcCtD
Crizotinib—Decreased appetite—Paclitaxel—lung cancer	3.83e-05	0.00052	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—lung cancer	3.81e-05	0.000518	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Paclitaxel—lung cancer	3.8e-05	0.000517	CcSEcCtD
Crizotinib—Fatigue—Paclitaxel—lung cancer	3.8e-05	0.000516	CcSEcCtD
Crizotinib—Asthenia—Gemcitabine—lung cancer	3.78e-05	0.000513	CcSEcCtD
Crizotinib—Constipation—Paclitaxel—lung cancer	3.77e-05	0.000512	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—lung cancer	3.74e-05	0.000508	CcSEcCtD
Crizotinib—Oedema—Docetaxel—lung cancer	3.74e-05	0.000507	CcSEcCtD
Crizotinib—ABCB1—respiratory system—lung cancer	3.73e-05	0.00068	CbGeAlD
Crizotinib—CYP3A5—lung—lung cancer	3.72e-05	0.00068	CbGeAlD
Crizotinib—Urethral disorder—Methotrexate—lung cancer	3.71e-05	0.000505	CcSEcCtD
Crizotinib—Infection—Docetaxel—lung cancer	3.71e-05	0.000504	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—lung cancer	3.71e-05	0.000504	CcSEcCtD
Crizotinib—Diarrhoea—Irinotecan—lung cancer	3.7e-05	0.000502	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—lung cancer	3.68e-05	0.000499	CcSEcCtD
Crizotinib—Shock—Docetaxel—lung cancer	3.67e-05	0.000499	CcSEcCtD
Crizotinib—Nervous system disorder—Docetaxel—lung cancer	3.66e-05	0.000498	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—lung cancer	3.65e-05	0.000497	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—lung cancer	3.65e-05	0.000497	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—lung cancer	3.65e-05	0.000496	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—lung cancer	3.63e-05	0.000493	CcSEcCtD
Crizotinib—Diarrhoea—Gemcitabine—lung cancer	3.6e-05	0.000489	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—lung cancer	3.58e-05	0.000487	CcSEcCtD
Crizotinib—AURKA—Teniposide—Etoposide—lung cancer	3.58e-05	0.0169	CbGdCrCtD
Crizotinib—Dizziness—Irinotecan—lung cancer	3.57e-05	0.000485	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—lung cancer	3.55e-05	0.000483	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—lung cancer	3.54e-05	0.000481	CcSEcCtD
Crizotinib—Asthenia—Cisplatin—lung cancer	3.52e-05	0.000478	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—lung cancer	3.52e-05	0.000478	CcSEcCtD
Crizotinib—Body temperature increased—Paclitaxel—lung cancer	3.48e-05	0.000473	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—lung cancer	3.46e-05	0.00047	CcSEcCtD
Crizotinib—Vomiting—Irinotecan—lung cancer	3.44e-05	0.000467	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—lung cancer	3.41e-05	0.000464	CcSEcCtD
Crizotinib—Rash—Irinotecan—lung cancer	3.41e-05	0.000463	CcSEcCtD
Crizotinib—Dermatitis—Irinotecan—lung cancer	3.4e-05	0.000462	CcSEcCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—lung cancer	3.38e-05	0.016	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—lung cancer	3.38e-05	0.016	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—lung cancer	3.38e-05	0.016	CbGdCrCtD
Crizotinib—Diarrhoea—Cisplatin—lung cancer	3.36e-05	0.000456	CcSEcCtD
Crizotinib—Paraesthesia—Docetaxel—lung cancer	3.35e-05	0.000456	CcSEcCtD
Crizotinib—Vomiting—Gemcitabine—lung cancer	3.35e-05	0.000455	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—lung cancer	3.34e-05	0.000454	CcSEcCtD
Crizotinib—Dyspnoea—Docetaxel—lung cancer	3.33e-05	0.000452	CcSEcCtD
Crizotinib—Rash—Gemcitabine—lung cancer	3.32e-05	0.000451	CcSEcCtD
Crizotinib—Dermatitis—Gemcitabine—lung cancer	3.32e-05	0.00045	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—lung cancer	3.3e-05	0.000448	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—lung cancer	3.29e-05	0.000447	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—lung cancer	3.26e-05	0.000444	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—lung cancer	3.25e-05	0.000441	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—lung cancer	3.24e-05	0.00044	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—lung cancer	3.23e-05	0.000439	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—lung cancer	3.23e-05	0.000439	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—lung cancer	3.22e-05	0.000438	CcSEcCtD
Crizotinib—Asthenia—Etoposide—lung cancer	3.22e-05	0.000438	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—lung cancer	3.22e-05	0.000438	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—lung cancer	3.22e-05	0.000437	CcSEcCtD
Crizotinib—Nausea—Irinotecan—lung cancer	3.21e-05	0.000436	CcSEcCtD
Crizotinib—Constipation—Docetaxel—lung cancer	3.19e-05	0.000434	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—lung cancer	3.16e-05	0.00043	CcSEcCtD
Crizotinib—Asthenia—Paclitaxel—lung cancer	3.16e-05	0.00043	CcSEcCtD
Crizotinib—Nausea—Gemcitabine—lung cancer	3.13e-05	0.000425	CcSEcCtD
Crizotinib—Vomiting—Cisplatin—lung cancer	3.12e-05	0.000424	CcSEcCtD
Crizotinib—ABCB1—epithelium—lung cancer	3.11e-05	0.000569	CbGeAlD
Crizotinib—Vision blurred—Methotrexate—lung cancer	3.11e-05	0.000422	CcSEcCtD
Crizotinib—Rash—Cisplatin—lung cancer	3.09e-05	0.00042	CcSEcCtD
Crizotinib—Dermatitis—Cisplatin—lung cancer	3.09e-05	0.00042	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—lung cancer	3.08e-05	0.000418	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—lung cancer	3.07e-05	0.000417	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—lung cancer	3.05e-05	0.000414	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—lung cancer	3.05e-05	0.000414	CcSEcCtD
Crizotinib—Diarrhoea—Paclitaxel—lung cancer	3.02e-05	0.00041	CcSEcCtD
Crizotinib—Dizziness—Etoposide—lung cancer	2.97e-05	0.000404	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—lung cancer	2.96e-05	0.000402	CcSEcCtD
Crizotinib—Body temperature increased—Docetaxel—lung cancer	2.95e-05	0.000401	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—lung cancer	2.95e-05	0.000401	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—lung cancer	2.93e-05	0.000398	CcSEcCtD
Crizotinib—Dizziness—Paclitaxel—lung cancer	2.91e-05	0.000396	CcSEcCtD
Crizotinib—Nausea—Cisplatin—lung cancer	2.91e-05	0.000396	CcSEcCtD
Crizotinib—Vomiting—Etoposide—lung cancer	2.86e-05	0.000388	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—lung cancer	2.86e-05	0.000388	CcSEcCtD
Crizotinib—Rash—Etoposide—lung cancer	2.83e-05	0.000385	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—lung cancer	2.83e-05	0.000385	CcSEcCtD
Crizotinib—Vomiting—Paclitaxel—lung cancer	2.8e-05	0.000381	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—lung cancer	2.8e-05	0.00038	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.79e-05	0.000379	CcSEcCtD
Crizotinib—Rash—Paclitaxel—lung cancer	2.78e-05	0.000378	CcSEcCtD
Crizotinib—Dermatitis—Paclitaxel—lung cancer	2.78e-05	0.000377	CcSEcCtD
Crizotinib—ABCB1—trachea—lung cancer	2.75e-05	0.000503	CbGeAlD
Crizotinib—Vision blurred—Doxorubicin—lung cancer	2.69e-05	0.000366	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—lung cancer	2.68e-05	0.000364	CcSEcCtD
Crizotinib—Infection—Methotrexate—lung cancer	2.67e-05	0.000363	CcSEcCtD
Crizotinib—Nausea—Etoposide—lung cancer	2.67e-05	0.000363	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—lung cancer	2.64e-05	0.000359	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—lung cancer	2.64e-05	0.000359	CcSEcCtD
Crizotinib—Nausea—Paclitaxel—lung cancer	2.62e-05	0.000356	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—lung cancer	2.61e-05	0.000355	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—lung cancer	2.56e-05	0.000348	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—lung cancer	2.56e-05	0.000347	CcSEcCtD
Crizotinib—Diarrhoea—Docetaxel—lung cancer	2.56e-05	0.000347	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—lung cancer	2.51e-05	0.000341	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—lung cancer	2.47e-05	0.000336	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—lung cancer	2.42e-05	0.000328	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.41e-05	0.000328	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—lung cancer	2.4e-05	0.000326	CcSEcCtD
Crizotinib—Vomiting—Docetaxel—lung cancer	2.37e-05	0.000323	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—lung cancer	2.37e-05	0.000322	CcSEcCtD
Crizotinib—Rash—Docetaxel—lung cancer	2.36e-05	0.00032	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—lung cancer	2.35e-05	0.00032	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—lung cancer	2.34e-05	0.000318	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—lung cancer	2.33e-05	0.000317	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—lung cancer	2.32e-05	0.000316	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—lung cancer	2.32e-05	0.000315	CcSEcCtD
Crizotinib—Infection—Doxorubicin—lung cancer	2.32e-05	0.000315	CcSEcCtD
Crizotinib—Shock—Doxorubicin—lung cancer	2.29e-05	0.000312	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—lung cancer	2.29e-05	0.000311	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—lung cancer	2.26e-05	0.000308	CcSEcCtD
Crizotinib—Nausea—Docetaxel—lung cancer	2.22e-05	0.000301	CcSEcCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—lung cancer	2.21e-05	0.0104	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—lung cancer	2.21e-05	0.0104	CbGdCrCtD
Crizotinib—ABCB1—bone marrow—lung cancer	2.18e-05	0.000399	CbGeAlD
Crizotinib—Body temperature increased—Methotrexate—lung cancer	2.13e-05	0.000289	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—lung cancer	2.09e-05	0.000284	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—lung cancer	2.08e-05	0.000282	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—lung cancer	2.05e-05	0.000279	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—lung cancer	2.03e-05	0.000275	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Gemcitabine—lung cancer	2.01e-05	0.00953	CbGdCrCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—lung cancer	2.01e-05	0.000273	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—lung cancer	2.01e-05	0.000273	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—lung cancer	1.99e-05	0.000271	CcSEcCtD
Crizotinib—ABCB1—lung—lung cancer	1.98e-05	0.000361	CbGeAlD
Crizotinib—Asthenia—Methotrexate—lung cancer	1.93e-05	0.000262	CcSEcCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—lung cancer	1.85e-05	0.00878	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—lung cancer	1.85e-05	0.00878	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—lung cancer	1.85e-05	0.00878	CbGdCrCtD
Crizotinib—Body temperature increased—Doxorubicin—lung cancer	1.84e-05	0.00025	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—lung cancer	1.84e-05	0.00025	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—lung cancer	1.78e-05	0.000242	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—lung cancer	1.73e-05	0.00817	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—lung cancer	1.73e-05	0.00817	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—lung cancer	1.73e-05	0.00817	CbGdCrCtD
Crizotinib—Vomiting—Methotrexate—lung cancer	1.71e-05	0.000233	CcSEcCtD
Crizotinib—Rash—Methotrexate—lung cancer	1.7e-05	0.000231	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—lung cancer	1.7e-05	0.00023	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—lung cancer	1.67e-05	0.000227	CcSEcCtD
Crizotinib—Nausea—Methotrexate—lung cancer	1.6e-05	0.000217	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—lung cancer	1.59e-05	0.000217	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—lung cancer	1.54e-05	0.000209	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—lung cancer	1.48e-05	0.000201	CcSEcCtD
Crizotinib—Rash—Doxorubicin—lung cancer	1.47e-05	0.0002	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—lung cancer	1.47e-05	0.0002	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—lung cancer	1.38e-05	0.000188	CcSEcCtD
Crizotinib—ABCB1—lymph node—lung cancer	1.35e-05	0.000247	CbGeAlD
Crizotinib—IRAK1—Signaling Pathways—MYC—lung cancer	2.6e-07	2.41e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—lung cancer	2.6e-07	2.41e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK3—lung cancer	2.6e-07	2.4e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—lung cancer	2.58e-07	2.38e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—lung cancer	2.57e-07	2.38e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—lung cancer	2.57e-07	2.38e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—lung cancer	2.57e-07	2.38e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—lung cancer	2.57e-07	2.38e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—lung cancer	2.56e-07	2.37e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HPGDS—lung cancer	2.56e-07	2.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—lung cancer	2.56e-07	2.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—lung cancer	2.56e-07	2.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—lung cancer	2.55e-07	2.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—lung cancer	2.55e-07	2.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.55e-07	2.36e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—lung cancer	2.55e-07	2.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—lung cancer	2.55e-07	2.35e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—lung cancer	2.55e-07	2.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—lung cancer	2.55e-07	2.35e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—lung cancer	2.54e-07	2.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—lung cancer	2.54e-07	2.35e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—lung cancer	2.54e-07	2.35e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—lung cancer	2.53e-07	2.34e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—lung cancer	2.53e-07	2.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—lung cancer	2.53e-07	2.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—lung cancer	2.51e-07	2.33e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—lung cancer	2.51e-07	2.33e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6R—lung cancer	2.51e-07	2.32e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—lung cancer	2.5e-07	2.31e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREBBP—lung cancer	2.5e-07	2.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—lung cancer	2.49e-07	2.3e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—lung cancer	2.49e-07	2.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—lung cancer	2.48e-07	2.29e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—lung cancer	2.48e-07	2.29e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—lung cancer	2.47e-07	2.29e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—lung cancer	2.47e-07	2.29e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—lung cancer	2.47e-07	2.29e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—lung cancer	2.47e-07	2.28e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—lung cancer	2.47e-07	2.28e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—lung cancer	2.46e-07	2.28e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—lung cancer	2.46e-07	2.28e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—lung cancer	2.46e-07	2.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2A6—lung cancer	2.46e-07	2.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCLC—lung cancer	2.46e-07	2.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—lung cancer	2.45e-07	2.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—lung cancer	2.45e-07	2.27e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—lung cancer	2.44e-07	2.26e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—lung cancer	2.44e-07	2.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—lung cancer	2.44e-07	2.25e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—lung cancer	2.43e-07	2.25e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—lung cancer	2.42e-07	2.24e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—lung cancer	2.42e-07	2.24e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—lung cancer	2.41e-07	2.23e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—lung cancer	2.4e-07	2.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—lung cancer	2.4e-07	2.22e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—lung cancer	2.4e-07	2.22e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—lung cancer	2.39e-07	2.22e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAF1—lung cancer	2.39e-07	2.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAP2K1—lung cancer	2.39e-07	2.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—lung cancer	2.39e-07	2.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—lung cancer	2.38e-07	2.2e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—lung cancer	2.38e-07	2.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—lung cancer	2.37e-07	2.19e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—lung cancer	2.37e-07	2.19e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—lung cancer	2.37e-07	2.19e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—lung cancer	2.36e-07	2.18e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—lung cancer	2.36e-07	2.18e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—lung cancer	2.35e-07	2.17e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CREBBP—lung cancer	2.35e-07	2.17e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—lung cancer	2.34e-07	2.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—lung cancer	2.34e-07	2.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—lung cancer	2.34e-07	2.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—lung cancer	2.33e-07	2.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—lung cancer	2.33e-07	2.16e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—lung cancer	2.33e-07	2.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—lung cancer	2.33e-07	2.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—lung cancer	2.32e-07	2.15e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—lung cancer	2.32e-07	2.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—lung cancer	2.32e-07	2.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—lung cancer	2.31e-07	2.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—lung cancer	2.3e-07	2.13e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—lung cancer	2.28e-07	2.11e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—lung cancer	2.28e-07	2.11e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—lung cancer	2.28e-07	2.11e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—lung cancer	2.28e-07	2.11e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—lung cancer	2.25e-07	2.08e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—lung cancer	2.25e-07	2.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—lung cancer	2.25e-07	2.08e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—lung cancer	2.25e-07	2.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—lung cancer	2.24e-07	2.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—lung cancer	2.23e-07	2.06e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—lung cancer	2.22e-07	2.06e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—lung cancer	2.22e-07	2.06e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—lung cancer	2.21e-07	2.05e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—lung cancer	2.21e-07	2.04e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—lung cancer	2.2e-07	2.04e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—lung cancer	2.2e-07	2.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—lung cancer	2.2e-07	2.03e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—lung cancer	2.2e-07	2.03e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—lung cancer	2.2e-07	2.03e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—lung cancer	2.19e-07	2.03e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—lung cancer	2.19e-07	2.02e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—lung cancer	2.18e-07	2.02e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—lung cancer	2.18e-07	2.02e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—lung cancer	2.16e-07	1.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—lung cancer	2.15e-07	1.99e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—lung cancer	2.15e-07	1.99e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—lung cancer	2.14e-07	1.98e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—lung cancer	2.14e-07	1.98e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—lung cancer	2.14e-07	1.98e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—lung cancer	2.14e-07	1.98e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—lung cancer	2.12e-07	1.97e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—lung cancer	2.12e-07	1.96e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—lung cancer	2.12e-07	1.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAF1—lung cancer	2.12e-07	1.96e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—lung cancer	2.1e-07	1.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—lung cancer	2.09e-07	1.94e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—lung cancer	2.09e-07	1.93e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOA1—lung cancer	2.09e-07	1.93e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—lung cancer	2.09e-07	1.93e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2E1—lung cancer	2.09e-07	1.93e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—lung cancer	2.09e-07	1.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—lung cancer	2.08e-07	1.93e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—lung cancer	2.07e-07	1.92e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—lung cancer	2.07e-07	1.92e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—lung cancer	2.07e-07	1.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—lung cancer	2.07e-07	1.91e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—lung cancer	2.07e-07	1.91e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—lung cancer	2.06e-07	1.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—lung cancer	2.06e-07	1.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—lung cancer	2.06e-07	1.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—lung cancer	2.06e-07	1.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—lung cancer	2.05e-07	1.9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—lung cancer	2.05e-07	1.89e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—lung cancer	2.04e-07	1.89e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—lung cancer	2.04e-07	1.88e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—lung cancer	2.03e-07	1.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—lung cancer	2.03e-07	1.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—lung cancer	2.02e-07	1.87e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—lung cancer	2.02e-07	1.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—lung cancer	2e-07	1.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—lung cancer	1.99e-07	1.84e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—lung cancer	1.98e-07	1.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—lung cancer	1.97e-07	1.82e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—lung cancer	1.96e-07	1.81e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—lung cancer	1.96e-07	1.81e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—lung cancer	1.95e-07	1.8e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—lung cancer	1.95e-07	1.8e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—lung cancer	1.94e-07	1.79e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—lung cancer	1.93e-07	1.78e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—lung cancer	1.92e-07	1.78e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—lung cancer	1.92e-07	1.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—lung cancer	1.91e-07	1.77e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—lung cancer	1.91e-07	1.77e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—lung cancer	1.9e-07	1.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—lung cancer	1.9e-07	1.76e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—lung cancer	1.9e-07	1.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—lung cancer	1.9e-07	1.76e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—lung cancer	1.9e-07	1.75e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—lung cancer	1.89e-07	1.75e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—lung cancer	1.88e-07	1.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—lung cancer	1.87e-07	1.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—lung cancer	1.87e-07	1.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—STK11—lung cancer	1.86e-07	1.72e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—lung cancer	1.85e-07	1.71e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—lung cancer	1.85e-07	1.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—lung cancer	1.82e-07	1.69e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—lung cancer	1.82e-07	1.68e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—lung cancer	1.8e-07	1.67e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—lung cancer	1.8e-07	1.67e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—lung cancer	1.8e-07	1.67e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—lung cancer	1.8e-07	1.67e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—lung cancer	1.8e-07	1.67e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—lung cancer	1.8e-07	1.66e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—lung cancer	1.8e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—lung cancer	1.8e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—lung cancer	1.79e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—lung cancer	1.79e-07	1.65e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CREBBP—lung cancer	1.77e-07	1.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—lung cancer	1.77e-07	1.64e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—lung cancer	1.75e-07	1.62e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—lung cancer	1.74e-07	1.61e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—lung cancer	1.73e-07	1.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—lung cancer	1.72e-07	1.6e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—lung cancer	1.72e-07	1.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—lung cancer	1.7e-07	1.58e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—lung cancer	1.68e-07	1.55e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—lung cancer	1.68e-07	1.55e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—lung cancer	1.68e-07	1.55e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—lung cancer	1.68e-07	1.55e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—lung cancer	1.68e-07	1.55e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—lung cancer	1.67e-07	1.54e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—lung cancer	1.66e-07	1.54e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—lung cancer	1.66e-07	1.53e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—lung cancer	1.64e-07	1.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—lung cancer	1.63e-07	1.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—lung cancer	1.63e-07	1.5e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—lung cancer	1.61e-07	1.49e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—lung cancer	1.61e-07	1.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—lung cancer	1.6e-07	1.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—lung cancer	1.6e-07	1.48e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—lung cancer	1.6e-07	1.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—lung cancer	1.59e-07	1.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—lung cancer	1.59e-07	1.47e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—lung cancer	1.59e-07	1.47e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—lung cancer	1.58e-07	1.47e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—lung cancer	1.57e-07	1.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—lung cancer	1.55e-07	1.43e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—lung cancer	1.54e-07	1.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—lung cancer	1.53e-07	1.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—lung cancer	1.5e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—lung cancer	1.5e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—lung cancer	1.49e-07	1.38e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—lung cancer	1.48e-07	1.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—lung cancer	1.47e-07	1.36e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—lung cancer	1.46e-07	1.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—lung cancer	1.45e-07	1.34e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—lung cancer	1.45e-07	1.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—lung cancer	1.44e-07	1.33e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—lung cancer	1.42e-07	1.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—lung cancer	1.42e-07	1.31e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—lung cancer	1.38e-07	1.27e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—lung cancer	1.37e-07	1.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—lung cancer	1.33e-07	1.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—lung cancer	1.32e-07	1.22e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOA1—lung cancer	1.29e-07	1.19e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—lung cancer	1.26e-07	1.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—lung cancer	1.26e-07	1.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—lung cancer	1.26e-07	1.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—lung cancer	1.22e-07	1.13e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—lung cancer	1.21e-07	1.12e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—lung cancer	1.18e-07	1.09e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—lung cancer	1.18e-07	1.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—lung cancer	1.17e-07	1.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—lung cancer	1.16e-07	1.08e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—lung cancer	1.12e-07	1.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—lung cancer	1.12e-07	1.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CREBBP—lung cancer	1.09e-07	1.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—lung cancer	1.03e-07	9.57e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—lung cancer	1.03e-07	9.52e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—lung cancer	1.02e-07	9.44e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—lung cancer	9.65e-08	8.93e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—lung cancer	9.01e-08	8.34e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—lung cancer	8.93e-08	8.26e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—lung cancer	8.92e-08	8.25e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—lung cancer	7.79e-08	7.2e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—lung cancer	7.43e-08	6.87e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—lung cancer	7.28e-08	6.74e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—lung cancer	5.49e-08	5.08e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—lung cancer	4.49e-08	4.15e-07	CbGpPWpGaD
